Latest Safety News

Castile Resources has integrated bismuth as a by-product into its Rover 1 Bankable Feasibility Study following China’s export restrictions, positioning itself as a key supplier amid global supply shocks. The company also advances exploration with innovative technology and secures strategic partnerships in critical mineral supply chains.

Australian Strategic Materials Limited (ASM) reminds eligible shareholders that its underwritten Share Purchase Plan closes on 17 July 2025, offering shares at a 20% discount. The plan is underwritten to $3 million by Canaccord Genuity, aiming to bolster ASM’s capital base.

Spacetalk Ltd has raised $3 million through convertible notes from its largest shareholder and converted $1 million of secured debt, positioning the company for international growth and new product development.

Imagion Biosystems has received encouraging feedback from the FDA on its planned Phase 2 HER2 breast cancer clinical trial, paving the way for its Investigational New Drug application submission later this year.

Neurizon Therapeutics has received positive feedback from the FDA on its plan to resolve the clinical hold on its ALS drug candidate NUZ-001, with key preclinical studies completed ahead of schedule. The company aims to resume clinical trials in late 2025.

Race Oncology has secured key ethics approvals to launch its Phase 1 RC220 trial at two major Hong Kong hospitals, marking a strategic expansion beyond Australia to accelerate patient recruitment and explore cardioprotective benefits.

Aurelia Metals has successfully met its FY25 production guidance across all key metals while strengthening its cash position to A$110 million, setting the stage for upcoming growth projects including the Great Cobar development.

Southern Palladium’s Optimised Prefeasibility Study reveals a $857 million project valuation and a 38% cut in peak capital expenditure through a staged development plan for its Bengwenyama PGM project in South Africa.

Anatara Lifesciences has strengthened its intellectual property portfolio with a Japanese patent for its GaRP gastrointestinal health product, while progressing pre-clinical studies in its Anti-Obesity Project. The company also confirmed registration of its R&D Tax Incentive application for 2024-2025.

Island Pharmaceuticals has accelerated its acquisition of the Galidesivir antiviral program from BioCryst Pharmaceuticals, adding a clinically advanced asset with significant US government backing and a promising regulatory pathway.

Sparc Technologies progresses its pioneering green hydrogen pilot plant and graphene-based coatings, backed by a significant government grant and a successful capital raise.

The Environmental Group Limited (ASX – EGL) has landed a $1.9 million contract to design and build its inaugural PFAS treatment plant, marking a key milestone in commercialising its proprietary environmental technology.